Patents by Inventor M. Patricia Beckmann

M. Patricia Beckmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against flt3-ligand
    Publication number: 20020160004
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to anti-flt3-L antibodies and enzyme-linked immunosorbent assays comprising such antibodies.
    Type: Application
    Filed: March 13, 2002
    Publication date: October 31, 2002
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • Ligands for flt3 receptors
    Publication number: 20020107365
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using fit3-L. Flt3 -L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Application
    Filed: October 25, 2001
    Publication date: August 8, 2002
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • DNA encoding interleukin-4 receptors
    Patent number: 6391581
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: May 21, 2002
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Cytokines that bind the cell surface receptor hek
    Publication number: 20020010325
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Application
    Filed: July 12, 2001
    Publication date: January 24, 2002
    Applicant: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Tumor Necrosis factor-alpha and -beta receptors
    Publication number: 20020006391
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Application
    Filed: January 12, 2001
    Publication date: January 17, 2002
    Inventors: Graig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Cytokines that bind the cell surface receptor Hek
    Patent number: 6274117
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: August 14, 2001
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Tumor necrosis factor-&agr; and -&bgr; receptors
    Patent number: 6224867
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: May 1, 2001
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Tumor necrosis factor receptor polypeptides recombinant P75 (Type II)
    Patent number: 6201105
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: March 13, 2001
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Methods of using Flt-3 ligand for exogenous gene transfer
    Patent number: 6190655
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: February 20, 2001
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • Antibodies that bind hek ligands
    Patent number: 5969110
    Abstract: Antibodies specific for a hek-L may be generated, using a hek-L polypeptide or fragment thereof as an immunogen. The antibodies may be monoclonal.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: October 19, 1999
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Purified p75 (type II) tumor necrosis factor receptor polypeptides
    Patent number: 5945397
    Abstract: Human tumor necrosis factor receptor proteins having the of amino acids 1-235 are disclosed in SEQ ID NO:2. TNF receptor deletion variants having the sequence of amino acids 1-185 or 1-163 of SEQ ID NO:2 also display TNF bing activity. Murine TNF receptor proteins are also disclosed in SEQ ID NO:4 and are capable of binding TNF.
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: August 31, 1999
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • DNA encoding interleukin-4 receptors
    Patent number: 5856296
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 5, 1999
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Methods of stimulating hematopoietic cells with flt3-ligand
    Patent number: 5843423
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: December 1, 1998
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • DNA encoding interleukin-4 receptors
    Patent number: 5840869
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: February 14, 1990
    Date of Patent: November 24, 1998
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Use of interleukin-4 receptors to inhibit biological responses mediated by interleukin-4
    Patent number: 5767065
    Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 16, 1998
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Cytokines that bind the cell surface receptor hek
    Patent number: 5738844
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 14, 1998
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Antibodies directed against elk ligand
    Patent number: 5728813
    Abstract: Antibodies to elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: March 17, 1998
    Assignee: Immunex Corporation
    Inventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum
  • Antibodies that are immunoreactive with interleukin-4 receptors
    Patent number: 5717072
    Abstract: Mammalian antibodies that are immunoreactive with Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, as well as antibodies that are immunoreactive with IL-4 receptors. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, involves administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 10, 1998
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors
    Patent number: 5712155
    Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: January 27, 1998
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors
    Patent number: RE36755
    Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: June 27, 2000
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann